A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

Name: A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
Creator: Vivli
Published: 2024-12-02 16:27:12
License: 暂无描述

DataCite Commons2024-12-02 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/00004954/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6 infection, with or without compensated cirrhosis respectively.

提供机构：

Vivli

创建时间：

2019-11-08